With an FDA de­ci­sion loom­ing, Dy­navax is shop­ping a deal on Hep­lisav — re­port

Late Fri­day Reuters re­port­ed that Dy­navax Tech­nolo­gies $DVAX was shop­ping its he­pati­tis B vac­cine Hep­lisav in the wake of a pos­i­tive FDA pan­el re­view and a shot at a near-term FDA ap­proval.

Quot­ing sources, the wire ser­vice re­port­ed that Dy­navax is en­gaged in a strate­gic re­view, with a chance of bag­ging a sale or li­cens­ing pact that could bring in a sub­stan­tial amount of cash. Reuters added that there is no guar­an­tee of a deal, as Dy­navax re­it­er­at­ed that it’s plan­ning a mar­ket launch for 2018. A com­pa­ny spokesper­son added: “We con­tin­ue to eval­u­ate any in­ter­est from po­ten­tial part­ners as part of our long-term strate­gic plan­ning.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER